慢性肾脏病肠道菌群失调的病理机制、治疗策略及中药的干预作用.docVIP

慢性肾脏病肠道菌群失调的病理机制、治疗策略及中药的干预作用 　　[摘要] ?c道菌群失调是中、晚期慢性肾脏病（chronic kidney disease，CKD）进展至尿毒症的高危因素之一，其特征就是益生菌减少、能产生尿毒素的条件致病菌（产尿素酶菌群、产内毒素菌群以及产代谢毒素菌群）增多。“肠-肾轴（gut-kidney axis）”学说和“慢性肾脏病-结肠轴（chronic kidney disease-colonic axis）”概念的核心观点认为，失调的肠道菌群通过加剧尿毒素蓄积和诱导全身性微炎症反应等途径加重肾脏的损伤。初步的临床试验和动物实验的结果显示，以乳酸菌和双歧杆菌制剂为代表的益生菌和以菊粉、低聚半乳糖为代表的益生元，还有鲁比前列酮、活性炭吸附剂等都可以针对CKD患者体内失调的肠道菌群，通过减轻尿毒素蓄积和抑制全身性微炎症反应等途径而改善肾功能。不仅如此，一些经口服或肠道给药的单味中药、中药复方还有中药提取物（大黄素等）在一定程度上也能调节肠道细菌，保护肠道上皮屏障，减轻尿毒素蓄积，延缓CKD进展。其中，大黄类经方――大黄甘草汤（浓缩颗粒TJ-84）改善肾衰竭动物模型体内尿毒素蓄积的靶点不是肾脏，而可能是“肠道菌群所启动的肠-肾轴”。基于此，针对中、晚期CKD患者肠组织中肠道菌群相关的病理因素（紧密连接蛋白、辅助性和调节性T细胞等）的干预性研究可能是今后的重点发展方向之一。 　　[关键词] 肠道菌群；中药；慢性肾脏病；肠-肾轴；病理机制 　　[Abstract] The gut microbiota dysbiosis is one of the risk factors in the progression from the advanced chronic kidney disease（CKD）to uremia， characterized by the reduction of probiotics and the increase of opportunistic pathogens including urease-related microbes， endotoxin-related microbes and toxin-related microbes， which can produce uremic toxins. According to the core point of the gut-kidney axis theory and the chronic kidney disease-colonic axis concept， the gut microbiota dysbiosis aggravates renal damage by accumulating uremic toxins and inducing the systemic micro-inflammation. The preliminary clinical trials and animal experiments show that the probiotics biologicals from Lactobacillus acidophilus or Bifidobacterium， and the prebiotics including inulin and galactooligosaccharides， as well as lubiprostone and activated carbon adsorbents can be used for improving dysfunction of CKD patients with the gut microbiota dysbiosis via reducing uremic toxins and inhibiting the systemic micro-inflammation. But not only that， it is reported that， to some extent， a number of the single Chinese herbal medicine（CHM）， the CHM prescriptions and the CHM extracts（emodin，etc.）with oral or enema administration can also regulate the gut microbiota dysbiosis， protect the intestinal epithelial barrier， reduce uremic toxins accumulation and delay CK